Member Info for LTbeliever

I believe this is the first ever mention of "goal of seeking GLOBAL licensing deals." In the past, it used to be about "initiating or further developing discussions with potential partners to support its efforts to secure a licensing option agreement or codevelopment agreement". DYOR

Psniffer, just to stir up a bit of excitement :) , how many millions of shares will u b be buying @0.15?

UNKNOWN, tnx for the informative post; just one clarification please - as we are still in the pre-clinical phase, you refer to "the next stage is almost certainly a milestone agreement on clinical trials to phase IIb" - not Phase I?

"the directors have prepared cashflow forecasts covering the period ending 31 December 2027 which take into account the likely run rate on overheads and planned research expenditure. After careful consideration, the directors consider that they have reasonable grounds to believe that the Group can be regarded as a going concern"

Tnx for correcting me WWT, it's always useful to hear from people with solid knowledge. Any other substance out there, if anyone knows, than can "modulate the inflammatory process sufficiently so that the natural immune repair process can take place"?

Soup, it looks like NPX002 not only relieves symptoms but also repairs IPF-affected tissue; is this the only substance in the IPF space that potentially does that?

Next RNS will be not about Placing, not about ODD, not something negative IMO, therefore in all likelihood it will be about a deal and/or the results of the additional studies. GLA

Info1, it's still progress; from "BS" to "BULL" :)))

Getting more focused and into a targeted approach in conjunction with partners' (not future ones!) feedback.

Thus, he is EXCITED,

Assessment of the likely inhaled human therapeutic window;

Continued investme and getting FEEDBACK from partners (not FUTURE partners); he omitted also the word "licensing" so maybe discussions are about co-developing?

Another point that has changed between NOW and January's release of AFS y/e 30 Sept 25 is the "list of activities being prioritised":

No more mention of -- "Assessment of the likely inhaled human therapeutic window;"

whereas this "Continued work with industry experts and key opinion leaders to create a clinical development strategy, cost and timeline" has changed to

"Continued work with industry experts and key opinion leaders to create A DATA PACKAGE SUPPORT PROGRAMME PROGRESSION AND BUSINESS DEVELOPMENT activities;

1. cash burn of appx 400k over 6 months, b/ce of appx 900k or less (minus Apr-May exps); this implies a cash burn of 65k per month, plus added expenses for the additional studies requested by partners; this means sufficient cash until a) studies are concluded and passed on to the partners b) until a deal is concluded (best scenario) c) hence, no fund raising in 2026 unless it's part of a deal (eg to co-develop NPX002);

2. Dan's progressively "bullish" language; now he says (MY CAPS) "March placing proceeds are allowing us to generate value-enhancing data and progress the NXP002 programme, aligning with FEEDBACK from potential partners and supporting our FOCUSED efforts to secure an out-licensing partner for NXP002. I remain EXCITED by our future prospects ..."

10 weeks ago, upon ODD designation, he was saying "ODD will be valuable for the potential FUTURE licensing partners we are in discussions with.."

Hopefully more to follow if good update tomorrow or Friday morning.

It's the CTO actually (CEO is his dad); but yes, I agree it's deserved; if the Co is making more cash now (hopefully more info soon) then fine.

We are getting Half year, to 31 March 2026, Report within the next few days (by mid-June) so the Co will update us on progress and cash burn to eoMarch; maybe the outlook for the next few months too.

I don't know but the 25mln BUY is mine; I reckon downside risk is about 10% (to 0.02) but the upside could be X times if we get good news next week or so (June oper. update); apart from Oil price jumping to $200, causing a global recession, I don't see a lot of risk especially if cash flows begin to build steadily. War or no war, the 3 major blocks (USA, EU and China) have to build stocks of metals for strategic reasons but also for the push to electrification, AI Data Centres etc; ignoring Africa for now, which is the next big area that needs lots of metals to develop (same as China 20 years ago); so the big picture for metals is positive, but hiccups expected along the way. If IRON can cover its opex soon, then the only way is up IMO; GLA, DYOR

Should be out in the next 3 days, barring any surprises; it'll be good to hear about the CTMs finally working properly and the 210k payment due since Q1 end; hopefully, some info on how SRB kits are selling and whether production & sales have restarted; also, how the planned increase in margins is progressing and whether productions bottlenecks for LXs (and FXs?) have been sorted out; a good update on Phase 2 of the PD detector re Cryptosporidium will also be welcome.

So, quite a few things to hear about, hopefully more good news than bad. GLA!

Lots of potential if PIP play their cards right. More traffic and freight slowly shifting on railroads, as energy becomes more expensive, pollution concerns in nations such as India and building of highways not cost efficient in huge, sparsely pop. places such as Canada and Australia. Question is, will TED cope with the potential increase in demand in a profitable manner? Maybe this is where Bayliss will come in?

Yes, the main obstacle is gone, the sale 'd proceed quickly now as it's been pending since Xmas! Let's see if this pushes the SP up a bit.

IMO, the potential range of outcomes is quite big (eg a small licensing fee of 10-15mln, to a bigger development p/ship for 50mln?) and the devil will be in the details; I prefer Dan not to rush but do his homework with the lawyers, the deal terms, deliverables' timelines etc because if the deal is with a big pharma then they will be calling the shots; if it's a smaller pharma, other issues eg its liquidity and ability to deliver whatever is agreed. I think Dan knows he cannot blow it this time (as with Oxilio) and the stakes are much bigger, so he will probably take his time.

That's appx 10% dilution over the current mkt cap; on the bullish side, this might indicate that the Co is doing very well so they can afford to reward Avi; but it'd have been better to just repay the loan owed to him (and thus reduce debt simultaneously with the cash going down) and leave the bonus next year maybe?